MedTrace Logo

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

NCT05007145 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2021-12-21

No results posted yet for this study

Summary

The purpose of this study is to explore the efficacy and safety of compare the efficacy and safety of PD-1 inhibitor and chemotherapy（treatment group） with chemoradiotherapy（control group） in neoadjuvant treatment of resectable thoracic esophageal squamous cell carcinoma.

Conditions

Interventions

DRUG

PD-1 inhibitor

PD-1 Inhibitor 200mg D1 Q3W

DRUG

Albumin-Bound Paclitaxel

125 mg/m\^2 D1/D8 Q3W

DRUG

Cisplatin

75 mg/m\^2 D1 Q3W

RADIATION

Radiation

40Gy/2.0Gy

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    collaborator INDUSTRY

  • Fujian Cancer Hospital

    lead OTHER_GOV

Principal Investigators

  • Shuoyan Liu · Fujian Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-15
Primary Completion
2023-08-31
Completion
2023-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05007145 on ClinicalTrials.gov